Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06679881 · ClinicalTrials.gov registry record · Phase 3
Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
A Phase 3 study of Hereditary Angioedema (HAE), sponsored by Pharvaris Netherlands B.V..
- Recruiting
- Registry status
- Phase 3
- Development phase
- 170
- Enrollment target
- 20
- Study locations
NCT06679881: Recruiting Phase 3 study of Hereditary Angioedema (HAE), sponsored by Pharvaris Netherlands B.V..
NCT06679881 is a Phase 3 study of Hereditary Angioedema (HAE) that is actively recruiting participants, run by Pharvaris Netherlands B.V.. The registered enrollment target is 170 participants, above the 43-participant average among 7 other Hereditary Angioedema (HAE) trials with a reported enrollment target (295% higher). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06679881, a Phase 3 study of Hereditary Angioedema (HAE), is actively recruiting participants, sponsored by Pharvaris Netherlands B.V..
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 170 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 3, multicenter, long-term, open-label study to evaluate the safety and efficacy of once-daily orally administered deucrictibant extended-release tablet for prophylaxis to prevent angioedema attacks in participants aged ≥12 years with Hereditary Angioedema
Conditions Studied
Interventions
- DRUG Deucrictibant
Study Locations (20)
Other
- Study Site - Melbourne
- Study Site - Melbourne
- Study Site - Perth
- Study Site - Vienna
- Study Site - Sofia
- Study Site - Montreal
- Study Site - Berlin
- Study Site - Frankfurt
- Study Site - Hong Kong
- Study Site - Dublin
- Study Site - Padua
- Study Site - Krakow
- Study Site - Cape Town
- Study Site - Daegu
- Study Site - Seoul
- Study Site - Barcelona
- Study Site - Brighton
California
- Study Site - Santa Monica
- Study Site - Walnut Creek
Missouri
- Study Site - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2025-02-01 |
| Est. Completion | 2028-12 |
| Phase | Phase 3 |
What NCT06679881 shows while recruiting
NCT06679881 is an interventional study that assigns participants to a tested intervention. The registered 170 participants enrollment target is mid-sized for trials with a published cap, above the 43-participant average among 7 other Hereditary Angioedema (HAE) trials with a reported enrollment target (295% higher).
The record links to 1 condition, with Hereditary Angioedema (HAE) appearing as the primary indexed condition, and to 1 intervention - of which Deucrictibant is the first listed.
NCT06679881 names 20 study sites across 3 states, led by Other, California, Missouri.
Frequently Asked Questions
What is clinical trial NCT06679881 about?
NCT06679881 is a clinical study titled "Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE". This is a Phase 3, multicenter, long-term, open-label study to evaluate the safety and efficacy of once-daily orally administered deucrictibant extended-release tablet for prophylaxis to prevent angioedema attacks in participants aged ≥12 years with Hereditary Angioedema
What is the current status of trial NCT06679881?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 170 participants. The study started on 2025-02-01. Estimated completion is 2028-12.
What conditions does trial NCT06679881 study?
This clinical trial studies the following conditions: Hereditary Angioedema (HAE).
What interventions are being tested in trial NCT06679881?
The interventions under investigation include: Deucrictibant (DRUG).
Who is sponsoring clinical trial NCT06679881?
This trial is sponsored by Pharvaris Netherlands B.V., which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06679881 being conducted?
This trial has 20 study locations across California, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hereditary Angioedema (HAE)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Navenibart in Participants With Hereditary Angioedema
RECRUITING · Phase 3
-
Donidalorsen Treatment in Children With Hereditary Angioedema
RECRUITING · Phase 3
-
Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
ACTIVE NOT RECRUITING · Phase 3
-
Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema
COMPLETED · Phase 3
-
Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients
RECRUITING · Phase 1
-
A Phase 2 in Adult Subjects With Hereditary Angioedema
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
- NCT04166409 · 170 participants · Phase 3
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI